StockNow
CalendarLog in
U.S. Markets

Bristol Myers Squibb (BMY) said a trial met its primary endpoint of overall response rate and key secondary endpoint of complete response rate in a heavily pretreated patient population exposed to a prior BCMA-targeted therapy

StockNow breaking-news AI analysis

Bristol Myers Squibb announced that its trial met both primary overall response rate and secondary complete response rate endpoints in heavily pretreated patients with prior BCMA therapy exposure.

1 stocks
BMYBristol-Myers Squibb Co.$66.43Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Qatar's Foreign Ministry says they are working with its regional partners and China to resume talks with the US and Iran

Politics

AstraZeneca (AZN LN) says Phase III tozorakimab data in COPD showed a 29%-34% reduction in exacerbations

AZNMarket Analysis

[MARKET UPDATE] Crude continues to climb, to the detriment of equity futures & fixed income, following the Saudi updates and ahead of the Houthi announcement